Biora's New Product Approved for Sale in the United States.Business/Health Editors MALMO, Sweden--(BUSINESS WIRE)--Jan. 30, 2001 Biora AB (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BIORY, SSE (1) An earlier full-screen editor in OS/2. (2) (Streaming SIMD Extensions) A series of additional instructions built into Pentium CPU chips for improved multimedia performance by performing mathematical operations on multiple sets of data at the : BIOR) announces today that, the Federal Drug Administration, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , has given Biora approval to sell its newest product for treatment of periodontitis periodontitis Inflammation of soft tissues around the teeth (see tooth). Poor dental hygiene leads to deposition of bacterial plaque on the teeth below the gum line, irritating and eroding nearby tissues. , Emdogain Gel, in the U.S. This is the largest market in the world- approximately 2.3 million procedures to regenerate tooth supporting structure are performed annually. Emdogain Gel is a further development of Emdogain that significantly simplifies its use. Instead of mixing two components manually, the dentist can immediately apply the ready-to-use product, Emdogain Gel. Rickard Soderberg, Biora's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , commented: "The approval by the FDA is very important to us. The product was launched in Europe in June last year and has been very well received by European dentists. Now, our U.S .subsidiary will immediately begin selling the product to the periodontists in the very large U.S. market." The U.S. is the single largest market for Biora with approximately 40% of total sales in 1999. Sales in the US during the period January-September 2000 increased by 60% compared to the same period in the previous year. Emdogain Gel has recently received approval in Brazil and Mexico as well. Biora develops manufactures and sells products for the treatment of periodontal disease Periodontal Disease Definition Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where and for use in oral surgery. Using its proprietary technology and expertise, Biora aims to become a world leader in biology-based products for specialized dental therapy. Biora's American Depository Shares are listed on the Nasdaq National Market in the US and Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries. in Sweden. This press release may contain certain forward- looking statements that relate to future events or future business and financial performance. Such statements can only be predictions and the actual events or results may differ from those discussed. The Company cautions that these statements are subject to important factors that could cause actual results to differ materially from those expressed or implied in such forward looking statements and are more fully discussed in periodic reports filed with Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion